#obesity treatment

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Lower-cost generic versions of semaglutide, the drug sold as Wegovy by Novo Nordisk for obesity, have begun reaching some countries and will soon arrive in others. At the same time, drugmakers are racing to develop newer GLP-1 medicines that are forecast to be more effective, cause fewer side effects and be easier to administer. London School of Economics professor Ken Shadlen, who studies the politics of pharmaceutical and health regulation, warns that obesity medications could become the next major battleground over access to medicines in lower-income countries. The shifts could put weight-loss treatment within reach of more people, but the path to access is far from settled.